Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment

Abstract

The rapid advancement of radiotherapy techniques and systemic anticancer agents has created unprecedented opportunities to improve outcomes for breast cancer patients, while also introducing new challenges related to optimal integration and safety. This consensus, convened by the Breast Cancer Committee of the Chinese Anti-Cancer Association and Chinese Society of Clinical Oncology Breast Cancer Committee, systematically evaluated available literature through November 2025 and employed Delphi methodology to generate evidence-based recommendations for combining radiotherapy with immune checkpoint inhibitors, targeted therapies, antibody–drug conjugates and endocrine agents across disease stages. This work aims to guide clinicians toward safer and more effective integration of radiotherapy with contemporary systemic treatments, promote consistency in clinical practice, and identify priority directions for future research to refine precision radiotherapy and systemic therapy combinations in breast cancer.

Keywords

breast cancer / combination treatment / radiotherapy / systemic agents

References

[1] B. Han, R. Zheng, H. Zeng, et al., “Cancer Incidence and Mortality in China, 2022,” Journal of the National Cancer Center 4 (2024): 47–53.

[2] M. A. Subhan, F. Parveen, H. Shah, et al., “Recent Advances With Precision Medicine Treatment for Breast Cancer Including Triple-Negative Sub-Type,” Cancers 15 (2023): 2204.

[3] S. Verma, S. Young, G. Boldt, et al., “Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review,” International Journal of Radiation Oncology 118 (2024): 1422–1434.

[4] S. M. Christ, F. Alongi, U. Ricardi, et al., “Cancer-specific Dose and Fractionation Schedules in Stereotactic Body Radiotherapy for Oligometastatic Disease: An Interim Analysis of the EORTC-ESTRO E2-RADIatE OligoCare Study,” Radiotherapy and Oncology 195 (2024): 110235.

[5] P. Nasa, R. Jain, and D. Juneja, “Delphi Methodology in Healthcare Research: How to Decide Its Appropriateness,” World Journal of Methodology 11 (2021): 116–129.

[6] B. Clyne, B. Tyner, M. O'Neill, et al., “ADAPTE With Modified Delphi Supported Developing a National Clinical Guideline: Stratification of Clinical Risk in Pregnancy,” Journal of Clinical Epidemiology 147 (2022): 21–31.

[7] F. Cardoso, S. Kyriakides, S. Ohno, et al., “Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 30 (2019): 1194–1220.

[8] K. S. Hughes, L. A. Schnaper, J. R. Bellon, et al., “Lumpectomy plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31 (2013): 2382–2387.

[9] I. H. Kunkler, L. J. Williams, W. J. L. Jack, et al., “Breast-Conserving Surgery With or Without Irradiation in Early Breast Cancer,” New England Journal of Medicine 388 (2023): 585–594.

[10] I. Meattini, M. C. De Santis, L. Visani, et al., “Single-Modality Endocrine Therapy Versus Radiotherapy After Breast-Conserving Surgery in Women Aged 70 Years and Older With Luminal A-Like Early Breast Cancer (EUROPA): A Preplanned Interim Analysis of a Phase 3, Non-Inferiority, Randomised Trial,” The Lancet Oncology 26 (2025): 37–50.

[11] S. R. D. Johnston, M. Toi, J. O'Shaughnessy, et al., “Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, HER2-Negative, Node-Positive, High-Risk Early Breast Cancer (monarchE): Results From a Preplanned Interim Analysis of a Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology 24 (2023): 77–90.

[12] D. Slamon, O. Lipatov, Z. Nowecki, et al., “Ribociclib Plus Endocrine Therapy in Early Breast Cancer,” New England Journal of Medicine 390 (2024): 1080–1091.

[13] Z. M. Shao, J. Hao, S. Wang, et al., “Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2- Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial,” Journal of Clinical Oncology 43 (2025): 515–515.

[14] H. S. Rugo, J. O'Shaughnessy, F. Boyle, et al., “Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study,” Annals of Oncology 33 (2022): 616–627.

[15] M. Y. Halyard, T. M. Pisansky, A. C. Dueck, et al., “Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831,” Journal of Clinical Oncology 27 (2009): 2638–2644.

[16] B. Bachir, S. Anouti, J. Abi Jaoude, et al., “Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab,” International Journal of Radiation and Oncology in Biology and Physics 113 (2022): 135–142.

[17] G. von Minckwitz, C.-S. Huang, M. S. Mano, et al., “Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer,” New England Journal of Medicine 380 (2019): 617–628.

[18] N. Masuda, S. J. Lee, S. Ohtani, et al., “Adjuvant Capecitabine for Breast Cancer After Preoperative Chemotherapy,” New England Journal of Medicine 376 (2017): 2147–2159.

[19] X. Wang, S. S. Wang, H. Huang, et al., “Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial,” Jama 325 (2021): 50–58.

[20] O. G. Trifanescu, L. M. Gales, A. Ciornei, et al., “Efficacy and Safety of Concurrent Capecitabine and Radiotherapy as Adjuvant Treatment in Triple Negative Breast Cancer,” Journal of Clinical Oncology 42 (2024): e12534–e12534.

[21] M. L. Balbach, A. D. Sherry, B. N. Rexer, et al., “Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial,” International Journal of Radiation and Oncology in Biology and Physics 118 (2024): 1262–1270.

[22] N. Kim, S. S. Kim, W. K. Cho, et al., “Concurrent Versus Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual Triple-Negative Breast Cancer After Neoadjuvant-Chemotherapy: A Multicenter Comparative Study,” International Journal of Radiation and Oncology in Biology and Physics 122 (2025): 72–83.

[23] P. Schmid, J. Cortes, L. Pusztai, et al., “Pembrolizumab for Early Triple-Negative Breast Cancer,” New England Journal of Medicine 382 (2020): 810–821.

[24] H. McArthur, J. Cortés, R. Dent, et al., “Abstract PD3-01: Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Post Hoc Analysis of Adjuvant Radiation Therapy in the Phase 3 KEYNOTE-522 Study,” Cancer Research 83 (2023): PD3–01.

[25] T. Tison, P. Loap, E. Arnaud, et al., “Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience,” Advances in Radiation Oncology 9 (2024): 101384.

[26] G. Chen, X. Gu, J. Xue, et al., “Effects of Neoadjuvant Stereotactic Body Radiotherapy plus Adebrelimab and Chemotherapy for Triple-Negative Breast Cancer: A Pilot Study,” Elife 12 (2023): e91737.

[27] A. N. J. Tutt, J. E. Garber, B. Kaufman, et al., “Adjuvant Olaparib for Patients With BRCA1- or BRCA2-Mutated Breast Cancer,” New England Journal of Medicine 384 (2021): 2394–2405.

[28] P. Loap, D. Loirat, F. Berger, et al., “Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial,” JAMA Oncology 8 (2022): 1802–1808.

[29] K. Liang, Y. Lu, W. Jin, et al., “Sensitization of Breast Cancer Cells to Radiation by Trastuzumab,” Molecular Cancer Therapeutics 2 (2003): 1113–1120.

[30] R. J. Pietras, J. C. Poen, D. Gallardo, et al., “Monoclonal Antibody to HER-2/Neureceptor Modulates Repair of Radiation-Induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene,” Cancer Research 59 (1999): 1347–1355.

[31] G. A. Ulaner, S. K. Lyashchenko, C. Riedl, et al., “First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients With Breast Cancer,” Journal of Nuclear Medicine 59 (2018): 900–906.

[32] H. Kurihara, A. Hamada, M. Yoshida, et al., “(64)Cu-DOTA-Trastuzumab PET Imaging and HER2 Specificity of Brain Metastases in HER2-Positive Breast Cancer Patients,” Ejnmmi Research 5 (2015): 8.

[33] E. Ippolito, S. Silipigni, P. Matteucci, et al., “Stereotactic Radiation and Dual human Epidermal Growth Factor Receptor 2 Blockade With Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series,” Cancers 14 (2022): 303.

[34] S. Pikis, G. Mantziaris, M. Protopapa, et al., “Stereotactic Radiosurgery for Brain Metastases From Human Epidermal Receptor 2 Positive Breast Cancer: An International, Multi-Center Study,” Journal of Neuro-Oncology 170 (2024): 199–208.

[35] Z. Ajgal, S. de Percin, V. Diéras, et al., “Combination of Radiotherapy and Double Blockade HER2 With Pertuzumab and Trastuzumab for HER2-Positive Metastatic or Locally Recurrent Unresectable and/or Metastatic Breast Cancer: Assessment of Early Toxicity,” Cancer Radiotherapie 21 (2017): 114–118.

[36] A. Aboudaram, P. Loap, D. Loirat, et al., “Pertuzumab and trastuzumab Combination With Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers With HER2 Receptor Overexpression,” Cancers 13 (2021): 4790.

[37] S. Ben Dhia, P. Loap, D. Loirat, et al., “Concurrent Radiation Therapy and Dual HER2 Blockade in Breast Cancer: Assessment of Toxicity,” Cancer Radiotherapie 25 (2021): 424–431.

[38] T. Huang, X. Luo, B. Wu, et al., “Pyrotinib Enhances the Radiosensitivity of HER2‑Overexpressing Gastric and Breast Cancer Cells,” Oncology Reports 44 (2020): 2634–2644.

[39] Z. Yang, J. Meng, X. Mei, et al., “Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial,” JAMA Oncology 10 (2024): 335–341.

[40] Y. Lin, M. Lin, J. Zhang, et al., “Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis,” Cancer research and treatment: official journal of Korean Cancer Association 52 (2020): 1059–1066.

[41] M. Anwar, Q. Chen, D. Ouyang, et al., “Pyrotinib Treatment in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data,” Clinical Cancer Research 27 (2021): 4634–4641.

[42] L. Dai, T. Gao, R. Guo, et al., “Efficacy and Safety of Pyrotinib-Based Regimens in HER2 Positive Metastatic Breast Cancer: A Retrospective Real-World Data Study,” Neoplasia 56 (2024): 101029.

[43] X. Liang, X. Gui, Y. Yan, et al., “Long-Term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study,” The Oncologist 29 (2024): e198–e205.

[44] J. Huang, S. Sun, Q. Tan, et al., “Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients With Brain Metastases: A Multicenter Real-World Study,” Clinical Breast Cancer 24 (2024): e509–e518.e1.

[45] J. Chen, H. Zhang, J. Zhou, et al., “Efficacy and Safety of Pyrotinib and Radiotherapy vs. Pyrotinib-Based Therapy in Patients With HER2+ Breast Cancer With Brain Metastasis: A Retrospective Cohort Study,” Annals of translational medicine 10 (2022): 1228.

[46] N. U. Lin, V. Borges, C. Anders, et al., “Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial,” Journal of Clinical Oncology 38 (2020): 2610–2619.

[47] V. M. Khatri, M. N. Mills, D. E. Oliver, et al., “Tucatinib and Stereotactic Radiosurgery in the Management of HER2 Positive Breast Cancer Brain Metastases,” Journal of Neuro-Oncology 164 (2023): 191–197.

[48] P. K. Stumpf, D. M. Cittelly, T. P. Robin, et al., “Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4,” Clinical Cancer Research 25 (2019): 3946–3953.

[49] A. Geraud, H. P. Xu, P. Beuzeboc, et al., “Preliminary Experience of the Concurrent Use of Radiosurgery and T-DM1 for Brain Metastases in HER2-Positive Metastatic Breast Cancer,” Journal of Neuro-Oncology 131 (2017): 69–72.

[50] H. Chen, K. J. Jerzak, et al., “Trastuzumab Emtansine Increases the Risk of Stereotactic Radiosurgery-Induced Radionecrosis in HER2 + Breast Cancer,” Journal of Neuro-Oncology 159 (2022): 177–183.

[51] E. S. Lebow, L. R. G. Pike, A. D. Seidman, et al., “Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases,” JAMA Oncology 9 (2023): 1729–1733.

[52] V. Salvestrini, K. Kim, S. Caini, et al., “Safety Profile of Trastuzumab-Emtansine (T-DM1) With Concurrent Radiation Therapy: A Systematic Review and Meta-Analysis,” Radiotherapy and Oncology 186 (2023): 109805.

[53] Y. Koide, N. Nagai, S. Adachi, et al., “Impact of Concurrent Antibody-Drug Conjugates and Radiotherapy on Symptomatic Radiation Necrosis in Breast Cancer Patients With Brain Metastases: A Multicenter Retrospective Study,” Journal of Neuro-Oncology 168 (2024): 415–423.

[54] A. Bardia, X. Hu, R. Dent, et al., “Trastuzumab Deruxtecan After Endocrine Therapy in Metastatic Breast Cancer,” New England Journal of Medicine 391 (2024): 2110–2122.

[55] S. Modi, W. Jacot, T. Yamashita, et al., “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” New England Journal of Medicine 387 (2022): 9–20.

[56] J. Cortés, S.-B. Kim, W.-P. Chung, et al., “Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer,” New England Journal of Medicine 386 (2022): 1143–1154.

[57] S. A. Hurvitz, R. Hegg, W.-P. Chung, et al., “Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer: Updated Results From DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial,” Lancet 401 (2023): 105–117.

[58] F. André, J. Cortés, G. Curigliano, et al., “A Pooled Analysis of Trastuzumab Deruxtecan in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases,” Annals of Oncology 35 (2024): 1169–1180.

[59] E. Ippolito, M. Benincasa, F. Pantano, et al., “Breast Cancer Trastuzumab-Deruxtecan and Radiotherapy: A Safety Sub-Analysis of Combart Prospective Cohort Study,” The Oncologist 30 (2025): oyaf229.

[60] J. Bouziane, P. Loap, S. Allali, et al., “Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2-Positive and HER2-Low Metastatic Breast Cancer: Assessing the Efficacy,” American Journal of Clinical Oncology 49 (2026): 33–38.

[61] K. Debbi, M. A. Benderra, J. Medioni, et al., “Safety and Efficacy of Combined Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer. The TENDANCE Multicentric French Study,” Breast 80 (2025): 104421.

[62] V. M. Khatri, M. A. Mestres-Villanueva, S. Yarlagadda, et al., “Multi-Institutional Report of Trastuzumab Deruxtecan and Stereotactic Radiosurgery for HER2 Positive and HER2-Low Breast Cancer Brain Metastases,” NPJ Breast Cancer 10 (2024): 100.

[63] A. Al-Rashdan, S. Quirk, M. Roumeliotis, et al., “Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-Institutional Safety and Toxicity Study,” International Journal of Radiation and Oncology in Biology and Physics 114 (2022): 399–408.

[64] E. Ippolito, L. Toppi, S. Carrafiello, et al., “Clinical Value of Bone Radiotherapy in a Prospective Cohort of Metastatic Breast Cancer Treated With Anti-CDK4/6,” Journal of Clinical Medicine 14 (2025): 4662.

[65] M. Kubeczko, D. Gabryś, A. Krzywon, et al., “Cyclin-dependent Kinase 4/6 Inhibitors Combined With Stereotactic Ablative Radiotherapy in Oligometastatic HR-Positive/HER2-Negative Breast Cancer Patients,” British Journal of Radiology 97 (2024): 1627–1635.

[66] M. Kubeczko, D. Gabryś, M. Gawkowska, et al., “Safety and Feasibility of Radiation Therapy Combined With CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer,” Cancers 15 (2023): 690.

[67] C. J. Lord and A. Ashworth, “PARP Inhibitors: Synthetic Lethality in the Clinic,” Science 355 (2017): 1152–1158.

[68] J. S. Witt, K. B. Wisinski, and B. M. Anderson, “Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier,” Clinical Breast Cancer 21 (2021): 120–127.

[69] M. F. Eren, A. Ay Eren, M. Sayan, et al., “The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis,” Medicina (Kaunas, Lithuania) 56 (2020): 348.

[70] F. André, E. Ciruelos, G. Rubovszky, et al., “Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 380 (2019): 1929–1940.

[71] L. A. Dunn, N. Riaz, M. G. Fury, et al., “A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent With Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma,” International Journal of Radiation and Oncology in Biology and Physics 106 (2020): 564–570.

[72] R. Roskoski, “Targeted and Cytotoxic Inhibitors Used in the Treatment of Breast Cancer,” Pharmacological Research 210 (2024): 107534.

[73] N. C. Turner, M. Oliveira, S. J. Howell, et al., “Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer,” New England Journal of Medicine 388 (2023): 2058–2070.

[74] L. Hopcroft, E. M. Wigmore, S. C. Williamson, et al., “Combining the AKT Inhibitor Capivasertib and SERD Fulvestrant Is Effective in Palbociclib-Resistant ER+ Breast Cancer Preclinical Models,” NPJ Breast Cancer 9 (2023): 64.

[75] A. Y. Ho, C. A. Barker, B. B. Arnold, et al., “A Phase 2 Clinical Trial Assessing the Efficacy and Safety of Pembrolizumab and Radiotherapy in Patients With Metastatic Triple-Negative Breast Cancer,” Cancer 126 (2020): 850–860.

[76] Y. Liu, Y. Hu, J. Xue, et al., “Advances in Immunotherapy for Triple-Negative Breast Cancer,” Molecular cancer 22 (2023): 145.

[77] S. L. Shiao, K. H. Gouin, N. Ing, et al., “Single-Cell and Spatial Profiling Identify Three Response Trajectories to Pembrolizumab and Radiation Therapy in Triple Negative Breast Cancer,” Cancer Cell 42 (2024): 70–84, e8.

[78] M. M. Yusof, D. W. Cescon, H. S. Rugo, et al., “43O Phase III KEYNOTE-355 Study of Pembrolizumab (Pembro) vs Placebo (Pbo) + Chemotherapy (Chemo) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC): Results for Patients (Pts) Enrolled in Asia,” Annals of Oncology 31, no. S6 (2020): S1257.

[79] Z. Jiang, Q. Ouyang, T. Sun, et al., “Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial,” Nature Medicine 30 (2024): 249–256.

[80] L. Chen, H. Li, H. Zhang, et al., “Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial,” Jama 333 (2025): 673–681.

[81] A. Bardia, S. A. Hurvitz, S. M. Tolaney, et al., “Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer,” New England Journal of Medicine 384 (2021): 1529–1541.

[82] H. S. Rugo, A. Bardia, F. Marmé, et al., “Overall Survival With Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial,” Lancet 402 (2023): 1423–1433.

[83] F. Martorana, M. V. Sanò, A. Fabi, et al., “A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer,” American Journal of Clinical Oncology 48 (2025): 450–457.

[84] D. Krug, J. Tio, A. Abaci, et al., “The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study,” Cancers 16 (2024): 1649.

[85] P. Loap, S. Chabli, P. Cottu, et al., “Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer,” American Journal of Clinical Oncology 48 (2025): 399–402.

[86] D. Hanna, S. Merrick, A. Ghose, et al., “Real World Study of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer in the United Kingdom,” British Journal of Cancer 130 (2024): 1916–1920.

[87] T. W.-W. Chen, M.-S. Dai, L.-M. Tseng, et al., “Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial,” JAMA Oncology 10 (2024): 325–334.

[88] C. Lévy, D. Allouache, J. Lacroix, et al., “REBECA: A Phase I Study of Bevacizumab and Whole-Brain Radiation Therapy for the Treatment of Brain Metastasis From Solid Tumours,” Annals of Oncology 25 (2014): 2351–2356.

[89] C. I. Tsien, S. L. Pugh, A. P. Dicker, et al., “NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 1285–1295.

[90] S. G. C. Kroeze, C. Fritz, M. Hoyer, et al., “Toxicity of Concurrent Stereotactic Radiotherapy and Targeted Therapy or Immunotherapy: A Systematic Review,” Cancer Treatment Reviews 53 (2017): 25–37.

[91] Y. Wang, E. Wang, L. Pan, et al., “A New Strategy of CyberKnife Treatment System Based Radiosurgery Followed by Early Use of Adjuvant Bevacizumab Treatment for Brain Metastasis With Extensive Cerebral Edema,” Journal of Neuro-Oncology 119 (2014): 369–376.

[92] B. M. Barney, S. N. Markovic, N. N. Laack, et al., “Increased Bowel Toxicity in Patients Treated With a Vascular Endothelial Growth Factor Inhibitor (VEGFI) After Stereotactic Body Radiation Therapy,” International Journal of Radiation and Oncology in Biology and Physics 87 (2013): 73–80.

[93] J. S. W. Lind, S. Senan, and E. F. Smit, “Pulmonary Toxicity After Bevacizumab and Concurrent Thoracic Radiotherapy Observed in a Phase I Study for Inoperable Stage III Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 (2012): e104–108.

[94] A. Dautruche, L. Belin, P. Cottu, et al., “Evaluation at 3 Years of Concurrent Bevacizumab and Radiotherapy for Breast Cancer: Results of a Prospective Study,” Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique l 22 (2018): 222–228.

[95] V. Pernin, L. Belin, P. Cottu, et al., “Radiotherapy Associated With Concurrent Bevacizumab in Patients With Non-Metastatic Breast Cancer,” Breast 23 (2014): 816–820.

[96] V. Pernin, L. Belin, P. Cottu, et al., “Late Toxicities and Outcomes of Adjuvant Radiotherapy Combined With Concurrent Bevacizumab in Patients With Triple-Negative Non-Metastatic Breast Cancer,” British Journal of Radiology 88 (2015): 20140800.

[97] A. Clément-Zhao, M.-L. Tanguy, P. Cottu, et al., “Toxicity of Locoregional Radiotherapy in Combination With Bevacizumab in Patients With Non-Metastatic Breast Cancer (TOLERAB): Final Long-Term Evaluation,” PLoS ONE 14 (2019): e0221816.

[98] H. Liu, B. Liu, Y. Ma, et al., “Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined With Apatinib: A Case Report and Literature Review,” Cancer Management and Research 13 (2021): 605–611.

[99] H. Pan, X. Zhou, L. Shen, et al., “Efficacy of Apatinib+Radiotherapy vs Radiotherapy Alone in Patients With Advanced Multiline Therapy Failure for Non Small Cell Lung Cancer With Brain Metastasis,” British Journal of Radiology 96 (2023): 20220550.

[100] J. Ma, J. Bi, X. Tuo, et al., “Efficacy and Safety of Apatinib Combined With Whole-Brain Radiation Therapy With a Simultaneous Integrated Boost for Brain Metastases From Non-Small Cell Lung Cancer: A Multicenter Retrospective Study,” Journal of Thoracic Disease 14 (2022): 455–463.

Rights & permissions

2026 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.